Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

This is a Phase II, single-arm clinical study designed to evaluate the efficacy and safety of Ipromlimab combined with Tuvonralimab, plus Albumin-Bound Paclitaxel and Nedaplatin, as neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.

NCT Number	NCT07374003
Lead Sponsor	Sun Yat-sen University
Conditions	Locally Advanced, Resectable
Enrollment	62 participants
Start Date	2025-12-17
Primary Completion	2029-06-20 (estimated)
Study Completion	2029-12-20 (estimated)
Updated on ClinicalTrials.gov	2026-01-28